Abstract
Background
The primary objective of the present trial was to assess the endometrial safety of a new oral contraceptive containing 4 mg drospirenone for a total duration of 13 cycles of 28 days each: 24 days of active treatment followed by 4 days placebo treatment per treatment cycle.
Materials and methods
This was a single-center, open-label, multiple-dose study on healthy female subjects at risk of pregnancy. Twenty one (= safety population set) pre-menopausal female Caucasian subjects started treatment with the study medication. The mean age was 29.0 years (range 19.0–36.0 years). Four subjects terminated the trial prematurely for the following reasons: on the subject’s request (n=2), due to an adverse event (n=1) and due to loss of contact (n=1). Seventeen subjects completed the planned duration of 13 cycles of open treatment with the test product (each cycle of 28 days).
Results
At visit 1 (pre-treatment), the biopsy result in the safety population set was proliferative in 14 cases and secretory in seven cases. At visit 7, four cases showed an inadequate result (insufficient tissue for diagnosis), 12 as proliferative and three as secretory. The number of biopsies with proliferative and secretory results reduced under treatment (safety population). The pre-post treatment changes in the endometrial biopsy results in the treatment completers set (n=17) showed almost no differences. At visit 1 (pre-treatment), the biopsy result was proliferative in 12 cases and secretory in five cases. At visit 7 (after 13 cycles of 28 days), four cases showed an inadequate result (insufficient tissue for diagnosis), 11 as proliferative, and two as secretory. The mean endometrial thickness in the safety population was reduced from 8.3 mm at visit 1 to 6.0 mm at visit 7. When comparing the endometrial thickness in the 21 subjects (safety population), the endometrial thickness showed a pre-post difference of 2.1 mm, whereas the endometrial thickness in the 17 study completers showed a pre-post difference of 2.5 mm (8.2 mm at visit 1–5.6 mm at visit 7).
Conclusions
Drospirenone 4 mg film-coated tablet in a dosage regime of 24/4 days is, regarding endometrial histology, a safe drug. Trial registration: EudraCT Register number: 2013-002300-13.
Research funding: None declared.
Conflict of interest: Pedro Antonio Regidor is Medical Director of Exeltis Healthcare.
Informed consent: An informed consent, given in the written form, was obtained by all participants.
Ethical approval: Ethical approval was obtained for the investigational center. The study documentation was reviewed and approved by the EC of on 17-Sep-2013. EudraCT Register number: 2013-002300-13.
References
[1] Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366:2257–66.10.1056/NEJMoa1111840Search in Google Scholar
[2] Archer DF, Ahrendt HJ, Drouin D. Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability. Contraception. 2015;92:439–44.10.1016/j.contraception.2015.07.014Search in Google Scholar
[3] Regidor PA. The clinical relevance of progestogens in hormonal contraception: present status and future developments. Oncotarget. 2018;9:34628–38.10.18632/oncotarget.26015Search in Google Scholar
[4] Medical eligibility criteria for contraceptive use. 5th ed. Geneva: World Health Organization; 2015.Search in Google Scholar
[5] Kiley JW, Shulman LP. Estradiol valerate and dienogest: a new approach to oral contraception. Int J Womens Health. 2011;3:281–6.10.2147/IJWH.S22645Search in Google Scholar
[6] McCann MF, Potter LS. Progestin-only contraception: a comprehensive review. Contraception. 1994;50(Suppl. 1):9–21.10.1016/0010-7824(94)90113-9Search in Google Scholar
[7] Rice C, Killick S, Hickling D, Coelingh Bennink H. Ovarian activity and vaginal bleeding patterns with a desogestrel-only preparation at three different doses. Hum Reprod. 1996;11:737–40.10.1093/oxfordjournals.humrep.a019245Search in Google Scholar
[8] Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Fertil Steril. 1950;1:3–25.10.1016/S0015-0282(16)30062-0Search in Google Scholar
[9] Jabbour HN, Kelly RW, Fraser HM, Critchley HO. Endocrine regulation of menstruation. Endocr Rev. 2006;27:17–46.10.1210/er.2004-0021Search in Google Scholar PubMed
[10] Smith OP, Critchley HO. Progestogen only contraception and endometrial breakthrough bleeding. Angiogenesis. 2005;8:117–26.10.1007/s10456-005-9003-zSearch in Google Scholar PubMed
[11] Kovacs G. Progestogen-only pills and bleeding disturbances. Hum Reprod. 1996;11(Suppl 2):20–3.10.1093/humrep/11.suppl_2.20Search in Google Scholar PubMed
[12] Collaborative Study Group. A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen only pills containing desogestrel 75 μg/day or levonorgestrel 30 μg/day. Eur J Contracept Reprod Health Care. 1998;3:169–78.10.3109/13625189809167250Search in Google Scholar
[13] Tchaikovski SN, Rosing J. Mechanisms of oestrogen-induced venous thromboembolism. Thromb Res. 2010;126:5–21.10.1016/j.thromres.2010.01.045Search in Google Scholar
[14] Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9. Br Med J. 2011;343:d6423.10.1136/bmj.d6423Search in Google Scholar
[15] Lindgren R, Risberg B, Hammar M, Berg G, Pryse-Davies J. Endometrial effects of transdermal estradiol/norethisterone acetate. Maturitas. 1992;15:71–8.10.1016/0378-5122(92)90064-BSearch in Google Scholar
[16] Weill A, Dalichampt M, Raguideau F, Ricordeau P, Blotière PO, Rudant J, et al. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. Br Med J. 2016;353:i2002.10.1136/bmj.i2002Search in Google Scholar
[17] Schindler AE. Differential effects on progestins on haemostasis. Maturitas. 2003;46:31–7.10.1016/j.maturitas.2003.09.016Search in Google Scholar
[18] Kuhl H. Effects of progestogens on haemostasis. Maturitas. 1996;24:1–19.10.1016/0378-5122(96)00994-2Search in Google Scholar
[19] Winkler UH. Hormone replacement therapy and haemostasis: principles of a complex interaction. Maturitas. 1996;24:131–45.10.1016/0378-5122(96)01027-4Search in Google Scholar
[20] Regidor PA, Colli E, Schindler AE. Drospirenone as oestrogen-free pill and haemostasis: coagulatory study results comparing a novel 4 mg formulation in a 24 + 4 cycle with desogestrel 75 μg per day. Gynecol Endocrinol. 2016;32:749–51.10.3109/09513590.2016.1161743Search in Google Scholar PubMed
[21] Merki GS. A study to evaluate the bioavailability of drospirenone in a new formulation of 4 mg 363 drospirenone compared to a formulation containing 3 mg drospirenone and 0.02 mg ethinylestradiol. 364 The 22nd World Congress on Controversies in Obstetrics, Gynecology & Infertility (COGI); 365 Budapest, Hungary. September 17–19, 2015.Search in Google Scholar
[22] Moreau C, Cleland K, Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception. 2007;76:267–72.10.1016/j.contraception.2007.06.008Search in Google Scholar PubMed
[23] Trussell J. Contraceptive failure in the United States. Contraception. 2011;83:397–404.10.1016/j.contraception.2011.01.021Search in Google Scholar
[24] Dallenbach-Hellweg G, Fenzel J. [Dependence of morphologic changes in portio, cervix and endometrium on dosage or potency of synthetic gestagens]. Geburtshilfe Frauenheilkd. 1985;45:238–43.10.1055/s-2008-1036451Search in Google Scholar
[25] Klebe U, Moltz L, Pickartz H. Effects of cyproterone acetate and ethinyl estradiol on endometrial histology. Arch Gynecol. 1983;234:113–20.10.1007/BF00207683Search in Google Scholar
[26] Bitzer J, Parke S, Roemer T, Serrani M. Endometrial safety of an oral contraceptive containing estradiol valerate and dienogest. Int J Womens Health. 2011;3:127–32.10.2147/IJWH.S18735Search in Google Scholar
[27] Lüdicke F, Johannisson E, Helmerhorst FM, Campana A, Foidart J, Heithecker R. Effect of a combined oral contraceptive containing 3 mg of drospirenone and 30 microg of ethinyl estradiol on the human endometrium. Fertil Steril. 2001;76:102–7.10.1016/S0015-0282(01)01834-9Search in Google Scholar
[28] Palacios S, Colli E, Regidor PA. Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone-only pill. Acta Obstet Gynecol Scand. 2019;98:1549–57.10.1111/aogs.13688Search in Google Scholar PubMed PubMed Central
© 2020 Walter de Gruyter GmbH, Berlin/Boston
